Treatment of secondary hyperparathyroidism in haemodialysis patients: a randomised clinical trial comparing paricalcitol and alfacalcidol
<p>Abstract</p> <p>Background</p> <p>Secondary hyperparathyroidism is a common feature in patients with chronic kidney disease. Its serious clinical consequences include renal osteodystrophy, calcific uremic arteriolopathy, and vascular calcifications that increase morb...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2009-09-01
|
Series: | BMC Nephrology |
Online Access: | http://www.biomedcentral.com/1471-2369/10/28 |